Recent Research Funding

Our faculty secure major research grants from various National Institutes of Health as well as private sources.

Chelsie Armbruster, PhD

  • Genetic susceptibility to mucosal infections with aging. Chelsie Armbruster (Co-Principal Investigator). NIAID-R21. $438,625. 6/1/2020-5/1/2022.
  • Conserved Proteus mirabilis genetic requirements for colonization of the catheterized urinary tract. Chelsie Armbruster (Principal Investigator). National Institute of Diabetes and Digestive and Kidney Diseases. $1,684,580. 9/1/2019-5/1/2024.

James Bangs, PhD

  • Secretory Protein Trafficking and Folding in African Trypanosomes. James Bangs (Principal Investigator). National Institutes of Health. $1,934,250. 7/1/2016-6/1/2021.

Ira Blader, PhD

  • TOXOPLASMA GONDII REGULATION OF HOST GABAERGIC SIGNALING. Ira Blader (Co-Principal Investigator). NIH/NIAID. 2/1/2016-1/1/2021.
  • GLYCOREGULATION OF SKP1 IN THE CYTOPLASM AND NUCLEUS. Ira Blader (Co-Principal Investigator). NIH/NIGMS. 1/1/2015-5/1/2019.
  • Control of Toxoplasma gondii Growth by the Host Cell Transcription Factor HIF1. Ira Blader (Co-Investigator). NIH/NIAID. 4/1/2006-1/1/2022.

Elsa Bou Ghanem, PhD

  • Genetic susceptibility to mucosal infections with aging. Elsa Bou Ghanem (Co-Principal Investigator). NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. $438,625. 6/1/2020-5/1/2022.
  • The efficacy of Liposomal Encapsulation of Polysaccharides pneumococcal vaccine in protecting aged hosts against invasive Streptococcus pneumoniae infections in murine models. Elsa Bou Ghanem (Co-Principal Investigator). NIA-R21. $436,310. 9/1/2019-6/1/2021.
  • The role of the extracellular adenosine pathway in age-driven decline in polymorphonuclear leukocyte (PMN) anti-pneumococcal responses. Elsa Bou Ghanem (Co-Principal Investigator). The University at Buffalo CTSI Translational Pilot Studies Program. $40,000. 4/1/2019-4/1/2020.
  • The role of extracellular adenosine in age-driven susceptibility to S. pneumoniae lung infection. Elsa Bou Ghanem (Principal Investigator). NIA-R00. $453,576. 9/1/2018-6/1/2021.

Anthony Campagnari, PhD

  • TARGETING M. CATARRHALIS FOR PREVENTION AND TREATMENT OF OTITIS MEDIA. Anthony Campagnari (Principal Investigator). National Institutes of Deafness and Communicative Disorders. $1,982,425. 5/1/2016-4/1/2021.
  • Pneumococcal transition from nasopharyngeal biofilm carriage to otitis media. Anthony Campagnari (Principal Investigator). NIH/NIDCD. $1,840,000. 3/1/2014-2/1/2019.

Terry Connell, PhD

  • Evaluation of a Specific Cytotoxic Agent and Identification of a New Targetable Receptor for Human TripleNegative Breast Cancer. Terry Connell (Co-Investigator). Dept. of Defense, BCRP, Breakthrough Award Levels 1. $375,000. 4/1/2018-3/1/2020.
  • Specific induction of lethal autophagy in triple-negative breast cancer cells. Terry Connell (Principal Investigator). National Cancer Institute, NIH. $275,000. 4/1/2017-3/1/2019.

Thomas Melendy, PhD

  • A novel DNA damage response that inhibits polyomavirus DNA replication. Thomas Melendy (Principal Investigator). NIAID. $436,190. 12/1/2016-11/1/2018.

John Panepinto, PhD

  • Regulation of Intrinsic Caspofungin Resistance in C. neoformans. John Panepinto (Principal Investigator). National Insitute of Allergy and Infectious Diseases. $412,353. 8/1/2018-7/1/2020.
  • Stress Responsive Reprogramming of Translating mRNA Pools in C. neoformans. John Panepinto (Principal Investigator). NIAID. $1,932,170. 5/1/2017-4/1/2022.
  • Control of Host-Induced C. neoformans Morphogenesis by Protein Arginine Methylation. John Panepinto (Principal Investigator). American Heart Association Founders Affiliate. $154,000. 1/1/2017-12/1/2019.

Laurie Read, PhD

  • Function and regulation of the essential RNA binding protein, DRBD18. Laurie Read (Principal Investigator). NIH. 6/1/2019-5/1/2024.
  • Functional characterization of RNA editing helicase 1. Laurie Read (Principal Investigator). NIH. 7/1/2018-6/1/2020.
  • Kinetoplastid RNA editing. Laurie Read (Principal Investigator). NIH. 7/1/2018-6/1/2022.

Spyridon Stavrou, PhD

  • The role of SERINC5 during retrovirus infection in vivo. Spyridon Stavrou (Principal Investigator). NIH/NIAID. $435,650. 1/1/2019-12/1/2021.
  • A3G induced virus evolution. Spyridon Stavrou (Principal Investigator). amfAR Foundation. $50,000. 4/1/2018-3/1/2019.

Yijun Sun, PhD

  • Stress responsive reprogramming of translating mRNA pools in C. neoformans. Yijun Sun (Co-Investigator). NIH. $2,000,000. 5/1/2017-4/1/2022.
  • Developing advanced algorithms to address major computational challenges in current microbiome research. Yijun Sun (Principal Investigator). NIH. $973,277. 7/1/2016-6/1/2019.
  • Oral microbiome and periodontitis: a prospective study in postmenopausal women. Yijun Sun (Co-Investigator), Michael Buck (Co-Investigator). NIH. $4,000,000. 7/1/2014-7/1/2019.

Elizabeth Wohlfert, PhD

  • ANTIBODY FRAGMENTS AS BIOCHEMICAL TOOLS TO INTERROGATE CD9 FUNCTION IN INFLAMMATORY DISEASES. Elizabeth Wohlfert (Co-Principal Investigator). NIGMS. $213,033. 5/1/2020-4/1/2022.